Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Alvotech - Ordinary Shares
(NQ:
ALVO
)
8.700
-0.050 (-0.57%)
Streaming Delayed Price
Updated: 3:22 PM EDT, Oct 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
217,923
Open
8.580
Bid (Size)
8.690 (4)
Ask (Size)
8.700 (6)
Prev. Close
8.750
Today's Range
8.430 - 8.700
52wk Range
7.350 - 13.70
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)
October 06, 2025
From
Kashiv BioSciences, LLC and Amneal Pharmaceuticals, Inc. and Alvotech and Advanz Pharma
Via
Business Wire
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
October 06, 2025
From
Alvotech
Via
GlobeNewswire
Performance
YTD
-33.9%
-33.9%
1 Month
+9.3%
+9.3%
3 Month
-0.3%
-0.3%
6 Month
+4.9%
+4.9%
1 Year
-29.8%
-29.8%
More News
Read More
This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
September 23, 2025
Via
Benzinga
Alvotech's Earnings: A Preview
August 12, 2025
Via
Benzinga
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
September 22, 2025
From
Alvotech
Via
GlobeNewswire
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
September 22, 2025
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
September 19, 2025
From
Alvotech
Via
GlobeNewswire
Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
September 04, 2025
From
Alvotech
Via
GlobeNewswire
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
August 21, 2025
From
Alvotech
Via
GlobeNewswire
Soho House, GoodRx Holdings, Dayforce And Other Big Stocks Moving Higher On Monday
August 18, 2025
Via
Benzinga
Alvotech SA (NASDAQ:ALVO) Surpasses Q2 2025 Estimates with Strong Revenue and EPS Growth
August 13, 2025
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
August 13, 2025
Via
Benzinga
Curious about the stocks that are showing activity after the closing bell on Wednesday?
August 13, 2025
Via
Chartmill
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
August 13, 2025
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
August 06, 2025
From
Alvotech
Via
GlobeNewswire
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
July 10, 2025
From
Alvotech
Via
GlobeNewswire
Earnings Scheduled For August 13, 2025
August 13, 2025
Via
Benzinga
Why Is Alvotech Stock Trading Higher On Wednesday?
July 09, 2025
Via
Benzinga
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland
July 09, 2025
From
Alvotech
Via
GlobeNewswire
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
July 01, 2025
From
Alvotech
Via
GlobeNewswire
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
June 26, 2025
From
Alvotech
Via
GlobeNewswire
Main Results of 2025 Annual and Extraordinary General Meeting
June 25, 2025
From
Alvotech
Via
GlobeNewswire
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
June 25, 2025
From
Alvotech
Via
GlobeNewswire
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
June 23, 2025
From
Alvotech
Via
GlobeNewswire
Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
June 11, 2025
From
Alvotech
Via
GlobeNewswire
Frequently Asked Questions
Is Alvotech - Ordinary Shares publicly traded?
Yes, Alvotech - Ordinary Shares is publicly traded.
What exchange does Alvotech - Ordinary Shares trade on?
Alvotech - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Alvotech - Ordinary Shares?
The ticker symbol for Alvotech - Ordinary Shares is ALVO on the Nasdaq Stock Market
What is the current price of Alvotech - Ordinary Shares?
The current price of Alvotech - Ordinary Shares is 8.700
When was Alvotech - Ordinary Shares last traded?
The last trade of Alvotech - Ordinary Shares was at 10/17/25 03:22 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.